Global Bioprocess Containers Market valued at $3 billion (2021) is set to witness a significant growth rate of 27% by 2026

Bioprocess Containers (BPCs) are ready-to-use single-use flexible container systems for major liquid handling applications in biopharmaceutical and biomanufacturing operations.

Benefits of Ready-To-Use Single-Use Bioprocess Container Systems fuels its Market Demand

Single-use technology (SUT) products are widely accepted for the manufacturing of vaccines and biologics. Some of the key benefits that are driving its demand are:

  • Operational Benefits & Reduced Risk of Cross-Contamination: Bioprocess container systems reduce the risk of cross-contamination. Moreover, the elimination of cleaning-in-place and sterilization-in-place (CIP/SIP) systems reduce setup, maintenance, and validation times, thereby enabling increased output.
  • Ready Integration: Bioprocess container components work well in all stages in the production of therapeutic biologics and vaccines.
  • Reduction in Cost of Goods Sold (COGS): Bioprocess container systems reduce capital investment and labor costs, which in turn leads to a reduction in COGS.
  • Scalability: Bioprocess container systems are well suited for use from benchtop to production scale processes.

High Development & Manufacturing Costs of Biologics Coupled with Its Patent Expiry Likely to Drive the Demand of Single-Use Bioprocessing Technologies

Biologics currently hold nearly half of the pharmacological market for oncology. By 2023, patents on nearly 20 oncology biologics are expected to expire. Patent expiry of biologics is expected to result in a rise in the R&D of biologics, and a turn shift of biologics from the pipeline stage to commercial production.

The development of biologics including cell & gene therapies and therapeutic vaccines demand high sterility and therefore biologics are increasingly being manufactured using single-use equipment and consumables.

As the development and manufacturing costs of biologics are very high, several biopharmaceutical manufacturers are incorporating single-use bioprocessing technologies into their development processes.

 “Biopharmaceutical manufacturers use a range of bioprocess containers (BPCs) during the production and storage of biopharmaceuticals. The trend of “single-use” or “disposable” BPC technologies in the biopharmaceutical industry enables greater flexibility and better use of production facilities that are increasingly designed for multiple products.” - Senior Director, Leading Bioprocess Container (BPC) Manufacturer, United States

Competitive Landscape Analysis: Bioprocess Containers Market

The global bioprocess containers market is marked by the presence of leading market players such as Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Merck Millipore (Germany), and others.

Get Customized Research Report on Bioprocess Containers Market @ https://meditechinsights.com/bioprocess-containers-market/

Comments

Post a Comment

Popular posts from this blog

Global Healthcare Companion Robots Market valued at about $3 billion (2020), is growing at a lucrative CAGR close to 20% through 2020-2025

Companion robots offer companionship and emotional support for the children, elderly, and disabled people. Over the years, the improvements in sensors, actuators, and AI have led to rise in interest in healthcare companion robots market. Rising aging population, the rising cost of elder care, and shortage of caregivers The population across the globe is aging and the number of caregivers in relation to the aging population is declining. In Japan, there will be an estimated shortage of 1 million caregivers by 2025. Moreover, the cost of elder care is also rising. Between 2019 and 2020, the cost of in-home care jumped by about 4.4%; assisted living costs surged by 6.2%; and nursing home costs increased by 3%. The use of robots instead could help reduce this cost. For instance, a monthly service contract for Stevie (a robot developed by Trinity College, Dublin) would likely run between 50-60% of the cost of hiring a human to do the same tasks, as per their claim. “The growing dispar...
Read more

Global Mycoplasma Testing Market is slated to see a lucrative growth rate of 11% by 2027

Mycoplasmas are the smallest known free-living microorganisms and are frequent contaminants of mammalian cell cultures. For the safety and purity of vaccines and other biological cell-derived products, it is crucial that the cell substrates and unprocessed bulk materials are free of adventitious agents, including mycoplasma.  In many cases, mycoplasmas vary from other forms of bacteria, making them difficult to culture and identify. Testing is done to detect mycoplasma like Mycoplasma hominis, Mycoplasma genitalium, Mycoplasma pneumoniae, and Ureaplasma urealyticum which can cause nongonococcal urethritis (NGU), prostate inflammation (prostatitis), vaginal discharge, and pelvic inflammatory disease (PID) in both men and women. Rising Concerns of Cell Culture Contamination to Trigger the Growth of the Global Mycoplasma Testing Market Mycoplasmas randomly contaminate the fluids used in the bioprocessing and cell culture. It is commonly known that primary cell cultures have a minimum...
Read more

Global Obesity Drugs Market valued at $2.3 billion in 2022, is expected to Witness a Healthy Growth of 25% by 2027

Obesity and overweight are defined as gain of additional fat thus leading to a number of diseases, which can be measured by using body mass index (BMI) as a baseline. A BMI of over 30 is generally considered as obese and a BMI of over 25 is considered as overweight. Obesity is a major risk factor to various diseases such as diabetes, heart diseases, and cancer; approximately over 650 million obese patients living across the world as as projected by World Health Organization (WHO). Rising Obese and Overweight Population to Trigger the Demand of Obesity Drugs Market Obesity is one of the topmost contributors to a number of medical diseases such as heart diseases, stroke, cancer and diabetes. World Obesity Atlas 2022 forecasted the growth of global obese population to be 16.1% in 2025, accounting for 892 million people which will further reach 1,025 million by 2030 with a healthy growth rate of 17.5% in 2030.  Some of the regional obesity burden estimated by World Obesity Atlas 202...
Read more